)
Visual
test
Olema Pharmaceuticals
Olema Pharmaceuticals (OLMA) investor relations material
Olema Pharmaceuticals Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary16 Mar, 2026
Executive summary
Advanced pivotal Phase 3 trials for palazestrant, including OPERA-01 (monotherapy) and OPERA-02 (combination with ribociclib), targeting ER+/HER2- metastatic breast cancer.
Initiated Phase 1b/2 study of palazestrant with Pfizer's atirmociclib and continued enrollment in OP-3136 studies.
Transformation into a fully integrated oncology company underway, with commercial launch preparations for late 2027.
Financial highlights
Ended 2025 with $505.4 million in cash, cash equivalents, and marketable securities, up from $434.1 million at year-end 2024.
Net loss for Q4 2025 was $46.1 million, and for the full year $162.5 million, compared to $33.6 million and $129.5 million in 2024.
Gross proceeds of $218.5 million raised from a public offering in November 2025.
GAAP R&D expenses for 2025 were $157.7 million, up from $124.5 million in 2024; non-GAAP R&D expenses were $145.5 million, up from $108.0 million.
GAAP G&A expenses for 2025 were $21.0 million, up from $17.7 million in 2024; non-GAAP G&A expenses were $15.6 million, up from $11.7 million.
Outlook and guidance
Top-line data from OPERA-01 expected in fall 2026; initial clinical results from OP-3136 anticipated in Q2 2026.
Commercial launch preparations underway for a potential approval in late 2027.
Rationale for atirmociclib combination study
Commercial infrastructure build-out for 2027
Success criteria for OP-3136 initial data
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Olema Pharmaceuticals
- Pivotal breast cancer trials advance with promising efficacy and key data readouts expected soon.OLMA
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Palazestrant and pipeline advances drive strong prospects in ER-positive breast cancer therapy.OLMAOppenheimer 36th Annual Healthcare Life Sciences Conference26 Feb 2026
- Palazestrant advances in pivotal trials, aiming to address major unmet needs in breast cancer.OLMACiti’s 2026 Virtual Oncology Leadership Summit19 Feb 2026
- Advancing late-stage breast cancer therapies with strong data and a shift toward commercialization.OLMAGuggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb 2026
- Palazestrant advances in pivotal trials, targeting major breast cancer markets with strong efficacy.OLMAMorgan Stanley 23rd Annual Global Healthcare Conference3 Feb 2026
- Palazestrant and KAT6 inhibitor advance in trials, targeting major unmet needs in breast cancer.OLMAMorgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026
- Key phase III data for palazestrant expected in 2024, with U.S. launch targeted for late 2027.OLMA44th Annual J.P. Morgan Healthcare Conference13 Jan 2026
- Late-stage pipeline targets $20B+ breast cancer market with pivotal data and launches by 2027.OLMACorporate presentation13 Jan 2026
- Upcoming data on palazestrant plus ribociclib may reshape the SERD/CDK4/6 landscape.OLMAJefferies London Healthcare Conference 202413 Jan 2026
Next Olema Pharmaceuticals earnings date
Q1 20268 May, 2026
Olema Pharmaceuticals
Next Olema Pharmaceuticals earnings date
Q1 20268 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage